ELI LILLY AND COMPANY Increase (Decrease) in Accounts and Other Receivables
ELI LILLY AND COMPANY (LLY) reported Increase (Decrease) in Accounts and Other Receivables of $7.00 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2026-02-12
- ELI LILLY AND COMPANY increase (decrease) in accounts and other receivables for fiscal 2025 was $7.00B, a 224.83% increase from fiscal 2024.
- ELI LILLY AND COMPANY increase (decrease) in accounts and other receivables for fiscal 2024 was $2.15B, a 12.08% decline from fiscal 2023.
- ELI LILLY AND COMPANY increase (decrease) in accounts and other receivables for fiscal 2023 was $2.45B, a 718.09% increase from fiscal 2022.
- ELI LILLY AND COMPANY increase (decrease) in accounts and other receivables for fiscal 2022 was $299.60M, a 76.56% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts and Other Receivables 12 month | Increase (Decrease) in Accounts and Other Receivables 12 month as first filed |
|---|---|---|
| 2025-12-31 | $7.00B 10-K · filed 2026-02-12 | |
| 2024-12-31 | $2.15B 10-K · filed 2026-02-12 | $2.16B 10-K · filed 2025-02-19 |
| 2023-12-31 | $2.45B 10-K · filed 2026-02-12 | |
| 2022-12-31 | $299.60M 10-K · filed 2025-02-19 | |
| 2021-12-31 | $1.28B 10-K · filed 2024-02-21 | |
| 2020-12-31 | $1.35B 10-K · filed 2023-02-22 | |
| 2019-12-31 | $127.20M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $996.70M 10-K · filed 2021-02-17 | |
| 2017-12-31 | $357.00M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $709.40M 8-K · filed 2019-10-24 | |
| 2015-12-31 | $304.50M 10-K · filed 2018-02-20 | |
| 2014-12-31 | -$117.40M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $152.70M 10-K · filed 2016-02-19 | |
| 2012-12-31 | -$361.80M 10-K · filed 2015-02-19 | |
| 2011-12-31 | $188.80M 10-K · filed 2014-02-19 | |
| 2010-12-31 | $319.10M 10-K · filed 2013-02-21 | -$319.10M 10-K · filed 2011-02-22 |
| 2009-12-31 | $492.90M 10-K · filed 2012-02-24 | -$492.90M 10-K · filed 2010-02-22 |
| 2008-12-31 | $799.10M 10-K · filed 2011-02-22 | |
| 2007-12-31 | -$842.70M 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |